[1] Israili ZH.Human alpha-1-glycoprotein and its interactions with drugs[J].Drug Metab Rev,2001, 33(2): 161-235. [2] Wang LS, Shang JJ, Shi SY,et al.Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage[J].Eur J Clin Pharmacol,2013, 69(5):1113-1120. [3] Tatman AJ, Wrigley SR, Jones RM. Resistance to atracurium in a patient with an increase in plasma alpha1 globulins[J].Br J Anaesth,1991, 67(5): 623-625. [4] Fink H, Luppa P, Mayer B, et al. Systemic inflammation leads to resistance to atracurium without increasing membrane expression of acetylcholine receptors[J].Anesthesiology,2003, 98(1): 82-88. [5] Materson BJ, Reda DH, Cushman WC, el al. Single-drug therapy for hypertension in men. A comparison of six antihypertesive agents with placebo[J].N Engl J Med,1993, 323(13) : 914-921. [6] Kishino S, Nomura A, Di ZS, et al. Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects[J].J Clin Pharmacol,1995, 35(5) : 510-514. [7] Lohoff M, Mak TW. Roles of interferon-regulatory factors in T-helper-cell differentiation[J].Nat Rev Immunol,2005, 5(2): 125-135. [8] Dilger JP, Ridal AM, Liu M, et al. Roles of amino acids and subunits in determining the inhibition of nicotinic acetylcholine receptors by competitive antagonists [J].Anesthesiology,2007, 106(6) : 1186-1195. (本文编辑:邓丽萍) [收稿日期] 2017-04-13
2017, Vol. 34 
